Gastric Cancer

  • A.T.R. Axon
  • M.R Dixon
  • H.M. Sue-Ling


Gastric cancer is the second commonest cause of death from malignancy in the world. It arises usually in a stomach that has been chronically inflamed over many years leading to a pan-gastritis, gastric atrophy, hypochlorhydria and intestinal metaplasia. Risk factors include a high salt, low vegetable and fruit diet, duodenogastric reflux and Helicobacter pylori infection. These, in conjunction with other environmental factors and a genetic predisposition, lead to the development of cancer mainly in middle aged and elderly people. Histologically carcinomas are classified as “intestinal” or “diffuse”; both however are strongly associated with infection with Helicobacter pylori. The classical triad of symptoms; abdominal pain, anorexia and weight loss is usually associated with advanced cancer which carries a poor prognosis. Early gastric cancer may be identified by screening programmes, active investigation of minor dyspeptic symptoms or those typically associated with peptic ulcer. If the lesion has not invaded the muscularis propria the prognosis is good. Early cancer if limited in extent can be treated by endoscopic mucosal resection (EMR), however most cases of cancer are treated by partial or total gastrectomy with or without adjuvant chemotherapy. Screening for gastric cancer is not available, or practicable in most countries. A more logical method to reduce mortality might involve screening for Helicobacter infection in young adults and treatment of affected individuals with antibiotic therapy. Prospective studies have not been carried out, but it is likely that this approach would allow effective primary prevention of this disease.


Gastric Cancer Pylorus Infection Early Gastric Cancer Advanced Gastric Cancer Intestinal Metaplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murray CJL, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990–2020 — global burden of disease study. Lancet 349: 1498–1504PubMedCrossRefGoogle Scholar
  2. 2.
    The Eurogast Study Group (1993). An international association between Helicobacter pylori infection and gastric cancer. Lancet 341: 1359–1362CrossRefGoogle Scholar
  3. 3.
    Helkobacter and Cancer Collaborative Group (2001). Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49: 347–353CrossRefGoogle Scholar
  4. 4.
    Kikuchi S, Wada O, Nakajima T, Nishi T, Kobayashi O, Konishi T, Inaba Y (1995). Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 75: 2789–2793PubMedCrossRefGoogle Scholar
  5. 5.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789PubMedCrossRefGoogle Scholar
  6. 6.
    International Agency for Research on Cancer (1994). Schistosomes, liver flukes and Helicobacter pylori. Monograph 61. Lyon, France: IARC: 177–240Google Scholar
  7. 7.
    Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M (1985). Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 35: 173–177PubMedCrossRefGoogle Scholar
  8. 8.
    Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M (1975). A model for gastric cancer epidemiology. Lancet ii: 58–60CrossRefGoogle Scholar
  9. 9.
    Drake IM, Mapstone NP, Schorah CJ, White KLM, Chalmers DM, Dixon MF, Axon ATR (1998). Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. Gut 42: 768–771PubMedCrossRefGoogle Scholar
  10. 10.
    Sobala GM, Schorah CJ, Shires S, Lynch DAF, Gallacher B, Dixon MF, Axon ATR (1993). Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 34: 1038–1041PubMedCrossRefGoogle Scholar
  11. 11.
    Lynch DAF, Mapstone NP, Clarke AMT, Sobala GM, Jackson P, Morrison L, Dixon MF, Quirke P, Axon ATR (1995). Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut 36: 346–350PubMedCrossRefGoogle Scholar
  12. 12.
    Watanabe T, Tada M, Nagai H, Sakaki S, Nakao M (1998). Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 115: 642–648PubMedCrossRefGoogle Scholar
  13. 13.
    Wang HH, Antonioli DA, Goldman H (1986). Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Human Pathology 17: 482–487PubMedCrossRefGoogle Scholar
  14. 14.
    Fletcher J, Wirz A, Young J, Vallance R, McColl KEL (2001). Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 121: 775–783PubMedCrossRefGoogle Scholar
  15. 15.
    Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KEL (2002). Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122: 1248–1257PubMedCrossRefGoogle Scholar
  16. 16.
    Busby WF, Shuker DEG, Charnley G, Newberne PM, Tannenbaum SR, Wogan GN (1985). Carcinogenicity in rats of the nitrosated bile acid conjugates N-nitrosoglycocholic acid and N-nitrosotaurocholic acid. Cancer Res 45:1367–1371PubMedGoogle Scholar
  17. 17.
    Miwa K, Hattori T, Miyazaki I. (1995) Duodenogastric reflux and foregut carcinogenesis. Cancer 75: 1426–32PubMedCrossRefGoogle Scholar
  18. 18.
    Lynch, D.A.F., Mapstone, N.P., Clarke, A.M.T., Jackson, P., Dixon, M.F., Quirke, P., Axon, A.T.R. (1995) Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection. Gut 36: 351–353.PubMedCrossRefGoogle Scholar
  19. 19.
    Murakami T (1971). Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. Gann Monogr Cancer Res 11: 53–55Google Scholar
  20. 20.
    Everett SM, Axon ATR (1997). Early gastric cancer in Europe. Gut 41: 142–150PubMedCrossRefGoogle Scholar
  21. 21.
    Mellinger JD, Ponsky JL (1991). Endoscopy in gastric malignancy. In: Sugarbaker P (ed) Management of gastric cancer. Kluwer Academic Publishers, Boston, volume 55: p 51–68CrossRefGoogle Scholar
  22. 22.
    Yoshida S (1998). Endoscopic diagnosis and treatment of early cancer in the alimentary tract. Digestion 59: 502–508PubMedCrossRefGoogle Scholar
  23. 23.
    Ribiero MM, Sarmento JA, Simoes S, Bastos J (1981). Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 47; 780–784CrossRefGoogle Scholar
  24. 24.
    Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, Saito T, Kawamura M, Kusano M, Kumagai K (2001). Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology 61: 212–20PubMedCrossRefGoogle Scholar
  25. 25.
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266; 2011–2015PubMedCrossRefGoogle Scholar
  26. 26.
    Yokozaki H, Yasui W, Tahara E (2001). Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 204; 49–95PubMedCrossRefGoogle Scholar
  27. 27.
    Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H (2001). Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 4: 113–121PubMedCrossRefGoogle Scholar
  28. 28.
    Hamamoto T, Yokozaki H, Senba S, Yasui W, Yunotani S, Miyazaki K, Tahara E (1997). Altered micro-satellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. J Clin Pathol 50; 841–846PubMedCrossRefGoogle Scholar
  29. 29.
    Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S (2001). DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 91; 205–212PubMedCrossRefGoogle Scholar
  30. 30.
    El-Omar E, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398–402PubMedCrossRefGoogle Scholar
  31. 31.
    Rebbeck TR (1997). Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epid Biomarkers & Prevention 6; 733–743Google Scholar
  32. 32.
    Sussman SK, Halvorsen RA, Illescas FF, et al (1988). Gastric adenocarcinoma: CT versus surgical staging. Radiology 167: 335–340PubMedGoogle Scholar
  33. 33.
    Dittler HJ, Siewert JR (1993). Role of endosonography in gastric carcinoma. Endoscopy 25: 162–166PubMedCrossRefGoogle Scholar
  34. 34.
    Gotoda T. Sasako M. Ono H. Katai H. Sano T. Shimoda T (2001) Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Brit J Surg 88; 444–449PubMedCrossRefGoogle Scholar
  35. 35.
    Maruyama K, Okabayashi K, Kinoshita T (1987). Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11: 418–425PubMedCrossRefGoogle Scholar
  36. 36.
    Cuschieri A, Weeden S, Fielding J, et al (1999). Patient survival after D1 and D2 resections for gastric cancer: long term results of the MRC randomized surgical trial. Br J Cancer 78: 1522–1530CrossRefGoogle Scholar
  37. 37.
    Sue-Ling HM, Johnston D, Axon ATR, et al (1993). Gastric cancer: a curable disease in Britain. Br Med J 307: 591–596CrossRefGoogle Scholar
  38. 38.
    Seymour MT, Dent JT, Papmichael D, et al (1999). Epirubicin, cisplatin and oral UFT with leucovorin (ECU): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. Ann Oncol 10: 1329–33PubMedCrossRefGoogle Scholar
  39. 39.
    Webb A, Cunningham D, Scarffe H, et alI (1997). Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–267PubMedGoogle Scholar
  40. 40.
    Earle CC, Maroun JA (1999). Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35: 1059–1064PubMedCrossRefGoogle Scholar
  41. 41.
    Hagiwara A, Takahashi T, Kojima O, et al (1992). Prophylaxis with carbonabsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339: 629–631PubMedCrossRefGoogle Scholar
  42. 42.
    Kim JP (1987). The concept of immunochemosurgery in gastric cancer. World J Surg 11: 4650–472CrossRefGoogle Scholar
  43. 43.
    Macdonald JS, Smalley S, Benedetti J, et al (2000). Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol 19: A1Google Scholar
  44. 44.
    Maruyama K, Gunven P, Okabayashi K, et al (1989). Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 210: 596–602PubMedCrossRefGoogle Scholar
  45. 45.
    Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P (on behalf of the Leeds HELP Study Group) (2002). The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharm Ther 16: 559–568.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • A.T.R. Axon
    • 1
  • M.R Dixon
    • 2
  • H.M. Sue-Ling
    • 3
  1. 1.Gastroenterology UnitThe General Infirmary, The Leeds Teaching HospitalsLeeds, LSI 3EX WestUK
  2. 2.Academic Unit of Pathological SciencesUniversity of LeedsLS2 9JT LeedsUK
  3. 3.Division of Surgery and Centre for Digestive DiseasesThe General InfirmaryLeeds LSI 3EXUK

Personalised recommendations